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ABSTRACT 22 
(1) Background and Aims: Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) found in 23 
fish oil are postulated to have favourable effects on platelet, endothelial and vascular function. We 24 
investigated whether EPA has differential effects on in vivo platelet aggregation and other markers 25 
of cardiovascular risk compared to DHA.  26 
(2) Methods and Results: Following a 2 wk run-in taking encapsulated refined olive oil, 48 healthy 27 
young men were randomly allocated using a parallel design to receive EPA-rich (3.1 g EPA /d) or 28 
DHA-rich (2.9 g DHA /d) triglyceride concentrates or refined olive oil (placebo), for a total 29 
supplementary lipid intake of 5g/d. The specified primary outcome was change in platelet monocyte 30 
aggregates (PMA); secondary outcomes were capillary density, augmentation index, digital pulse 31 
volume measurements, 24 h ambulatory BP, plasma 8-isoprostanes-F2α. Changes in the proportions 32 
of DHA and EPA in erythrocytes and non-esterified fatty acid composition indicated compliance to 33 
the intervention. There was no significant treatment effect on PMA (P=0.382); mean changes (%) 34 
(95% CI) were placebo -0.5 (-2.0, 1.04), EPA 0.4 (-0.8, 1.6), DHA 0.3 (-1.5, 2.0). R-QUICKI, an 35 
index of insulin sensitivity, was greater following EPA compared to placebo (P< 0.05).  No other 36 
significant differences were noted. 37 
(3) Conclusion: Neither EPA- nor DHA-rich fish oil supplementation influence platelet-monocyte 38 
aggregation or several markers of vascular function after 6 wk in healthy young males. This trial 39 
was registered at clinicaltrials.gov as NCT01735357.  40 
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INTRODUCTION 41 
Epidemiological and observational studies support the theory that fish or fish oil consumption 42 
reduces the risk of cardiovascular disease (CVD) [1], while recent meta-analyses found no 43 
association between n-3 polyunsaturated fatty acids (n-3 PUFA) supplementation and CVD death, 44 
or events [2]. Studies vary in design, populations, duration and doses, as well as the respective 45 
ratios of EPA and DHA used, and investigations into their separate effects are limited [3].  46 
Endothelial dysfunction characterizes the initiating stage of atherogenesis, and is closely linked to 47 
platelet activation. Nitric oxide produced by the endothelium plays a crucial role in platelet 48 
activation, including P-selectin expression and platelet-monocyte aggregation [4]. Platelet-49 
monocyte aggregates (PMA) constitute an early marker of CVD risk [5] and are believed to be a 50 
more accurate indicator of true in vivo platelet function compared to ex vivo measures of platelet 51 
aggregation, and also to other in vivo measures like platelet surface P-selectin [6, 7]. On the other 52 
hand, platelet activation promotes the homing of endothelial progenitor cells (EPCs) to the sites of 53 
endothelial injury and favours their differentiation into endothelial cells [8]. The postulated anti-54 
thrombotic actions of fish oils have been mostly attributed to the ability of EPA to compete with 55 
arachidonic acid (AA) in the cyclooxygenase (COX) pathway, leading to the formation of 56 
eicosanoids that are less pro-thrombotic than the eicosanoids derived from AA [9]. Both EPA and 57 
DHA may also give rise to the production of protectins and resolvins that appear to have potent 58 
anti-inflammatory actions [9], and may also directly inhibit platelet aggregation [10], which may 59 
account for the anti-thrombotic actions of n-3 PUFAs. On the other hand, the additional double 60 
bond in DHA may lead to a greater effect on platelet membrane fluidity compared to EPA [11]. 61 
EPA and DHA may also enhance endothelial function [12, 13] and improve EPC functionality and 62 
numbers in vitro [14] and in healthy subjects at moderate risk of CVD [15], possibly by modulating 63 
mobilization, adhesion and angiogenesis mediated by changes in eicosanoid metabolism and/or 64 
nitric oxide signalling.  65 
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In healthy young men, oily fish consumption (providing ~ 1 g EPA+DHA/d) for 4 wk reduced 66 
PMA by 35% [16] and the present study set out to determine whether this effect was primarily 67 
influenced by EPA or DHA. It should be noted, however, that the study was designed before the 68 
publication of further findings from the same group in 2013, showing that fish oil supplementation 69 
(2g/d, 6wks) did not affect PMA in CHD patients [17], nor in cigarette smokers [18]. The overall 70 
aim was to determine whether supplementation with oils enriched with either EPA or DHA, had 71 
differential effects on markers of platelet, endothelial and vascular function in healthy young males. 72 
Our primary outcomes included PMA and numbers of EPC, as a putative marker of endothelial 73 
repair [19]. However, EPCs are very rare events and account for 0.0001 - 0.01% of all mononuclear 74 
cells. Technical difficulties were encountered in the EPC method, which did not allow the recording 75 
of sufficient events to provide accurate results. Thus only the PMA data are reported as primary 76 
outcomes. Secondary outcomes included finger capillary density (a marker of microvascular 77 
function), plasma 8-isoprostane-F2α, arterial stiffness (digital and radial pulse wave analysis), 78 
ambulatory blood pressure (BP) / heart rate (HR) measurement, and circulating markers of 79 
metabolic dysregulation. 80 
 81 
METHODS 82 
Participants 83 
Ethical approval was granted by the Bromley Research Ethics Committee, London in April 2009 84 
(ref. 08/H0805/2) and informed consent was obtained from all participants. Healthy males (aged 18-85 
45 y) were recruited through internal e-mail circulars and posters among King’s College London 86 
students and staff, and fitness centre users in the vicinity. Exclusion criteria were history of CVD, 87 
diabetes (or fasting glucose ≥ 6.1 mmol/L), cancer, kidney, liver or bowel disease; gastrointestinal 88 
disorder or use of drug altering nutrient absorption; smoking, history of substance abuse or 89 
alcoholism (>60 units/wk); current alcohol intake > 28 units/wk; BP > 160/90 mmHg, fasting blood 90 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
5 
 
cholesterol > 6.5 mmol/L; fasting triacylglycerol concentrations > 2.0 mmol/L, platelet count above 91 
or below the normal range or any history indicative of a congenital or acquired platelet or 92 
haemostatic defect and recent use of associated medications; allergy or intolerance to study 93 
capsules; current consumption of >1 portion oily fish/wk; weight change of >3 kg in preceding 2 94 
months; BMI <18 and >32 kg/m2. At screening participants filled in a questionnaire on their general 95 
health, alcohol and fish consumption; BP, height and weight, body fat percentage, waist and hip 96 
circumference were measured, and blood was tested for liver function, fasting glucose, insulin, lipid 97 
profile and full blood count. 98 
Intervention 99 
The single-blind, randomized, placebo-controlled, parallel study ran from June 2009 to May 2010. 100 
Power calculations were based on 16 subjects per group completing the study to give an 80% power 101 
to detect a 10% unit difference in mean PMA at a significance level of 0.05, using standard 102 
deviations and expected changes from a previous study [16]. Following a run-in period (5 g refined 103 
olive oil/d for 2 wk), participants were randomly assigned to receive either EPA-, DHA-rich oils, or 104 
refined olive oil (British Pharmacopoeia specification, maximum unsaponifiable matter 1.5 %) in 105 
the form of purified triglycerides in soft gel capsules (IncromegaTM EPA500TG SR, DHA500TG 106 
SR and refined olive oil capsules were provided by Croda Chemicals Europe Ltd, UK). EPA- and 107 
DHA-rich oils were blended with refined olive oil and calculations were made to reach a 108 
consumption of ~3 g/d of EPA (3.1 g EPA + 0.10 g DPA + 0.71 g DHA) or DHA (2.9 g DHA + 109 
0.17 g DPA + 0.52 g EPA) for a total lipid intake of 5g/d. During the intervention, participants were 110 
asked to avoid medications and consumption of oily fish and dietary supplements. Compliance to 111 
treatment was assessed by the incorporation of EPA and DHA into erythrocyte membrane. The 112 
composition of NEFA was also assessed as changes in their levels and proportions may impact 113 
endothelial and vascular function [20]. 114 
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Data collection 115 
Participants attended the Metabolic Research Unit at King’s College London in the morning at the 116 
end of the 2-wk run-in period and of the 6-wk treatment phase. Participants were instructed to 117 
consume a low fat evening meal, fast overnight, and avoid drinking alcohol, caffeine and taking part 118 
in any strenuous exercise during the day preceding their visit. Ambulatory BP monitors were 119 
collected, weight and body composition, seated BP and HR were measured (Omron 705IT). The 120 
participant was then asked to rest quietly in the supine position for the vascular measurements 121 
(pulse wave analysis - PWA, digital volume pulse - DVP, capillaroscopy), after which a fasting 122 
blood sample was collected into evacuated containers (Becton Dickinson) for biochemical analysis.  123 
Measurement of PMA by flow cytometry 124 
Samples were analyzed on an FC500-Beckman Coulter flow cytometer. Blood for PMA analysis 125 
was drawn into citrated tubes and kept at room temperature (RT) until analysis within 15 min. The 126 
protocol for PMA analysis was adapted from Goodall et al [7]. PMA were identified by the co-127 
expression of CD14 and CD42b (or P-selectin), specifically expressed by monocytes and activated 128 
platelets, respectively. Results are expressed as a percentage of total CD14+ events, the gating 129 
strategy is described in details in supplement material 1. A blocking mouse immunoglobulin 130 
(MOPC31) was used to block Fc binding and non specific binding of monoclonal antibodies to 131 
leukocytes. In addition, a CD62P monoclonal antibody blocker was used to block P-selectin binding 132 
which may encourage ex-vivo binding of platelets to leukocytes. 50 µL of whole blood and 50 µL of 133 
HBS buffer were incubated with the appropriate antibody for 30 min at RT, and 250 µl of 134 
Optilyse®C solution were added. 250 µl PBS were added after 15 min and the samples were 135 
allowed to stand another 5 min at RT prior to the flow cytometry analysis. The acquisition time was 136 
200s and the total events were 25,874 +/- 9,180 and 24,968 +/- 9,024 events for the first and second 137 
visit, respectively. 138 
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Capillaroscopy 139 
Room temperature was recorded prior to the vascular measurements and remained constant at 24.2 140 
+/- 0.4 °C. Capillary density was measured using the CAM1 Capillary Anemometer and CapiScope 141 
Image Acquisition and Analysis software  (KK Research Technology Ltd, UK), which allows 142 
visualization, capture and storage of video capillaroscopy images onto a computer. Capillaroscopy 143 
images were made with participants resting in the supine position. The left hand and forearm were 144 
supported at heart level and immobilized using a splint surrounded by cushioning, so that the left 145 
anular finger (4th digit) could be placed in a finger clamp underneath the CAM1 system camera. A 146 
drop of vegetable oil was applied to the skin measurement area to minimize light reflection. Five 147 
images were taken at the dorsum of the middle phalanx, away from the nail fold, where capillaries 148 
are perpendicular to the skin, in order to measure functional capillary density as the mean of the 149 
capillary counts from each image. The day to day reproducibility of the technique was 4.2% and 150 
within-day intra-observer reproducibility was 7.1%.  151 
Vascular measurements, ambulatory blood pressure and heart rate monitoring  152 
Ambulatory BP was monitored over 24h two to three days prior to each visit (TM-2430, A&D 153 
Instrument Ltd,  U.K.) as previously described [21]. Data were transferred to a computer and 154 
analysed using the software provided by the manufacturer. PWA (SphygmoCor Px apparatus with 155 
SphygmoCor analysis software, version 7.01, AtCor Medical Pty Limited) and DVP stiffness index 156 
and reflection index (DVP-SI and DVP-RI respectively, PulseTrace PCA 2, Micro Medical Ltd) 157 
were performed as described earlier [22, 23] in the supine position after 15 min rest. They were 158 
carried out in triplicate on the left arm while BP was measured concurrently on the right arm 159 
(Omron 705IT). 160 
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Plasma isoprostane concentrations, lipid profiles and markers of glucose 161 
homeostasis/insulin resistance 162 
8-isoprostane F2α  analysis was performed as previously described [22]. Briefly, blood was drawn 163 
into citrated tubes, treated with indomethacin (15 µmol/L) and BHT (20 µmol/L) and stored at -164 
80°C until measurement by GC/MS (Agilent Technologies 6890N/5673). Fasting venous blood was 165 
collected into evacuated containers: fluoride oxalate tubes for glucose, lithium heparin for insulin 166 
and EDTA vacutainers for lipids. Plasma glucose and serum triglycerides, cholesterol, and HDL 167 
cholesterol concentrations were measured using standard enzymatic assays. LDL cholesterol was 168 
calculated using the Friedwald formula. Apolipoprotein B was measured by a polyethylene glycol 169 
enhanced immunoturbidimetric assay (Siemens Healthcare Diagnostics, UK) . Total serum non-170 
esterified FA (NEFA) were measured using an enzymatic colorimetric method assay (NEFA-HR(2) 171 
Assay kit, WAKO Chemicals Gmbh, Germany). Insulin was measured by ELISA (Siemens 172 
Healthcare Diagnostics Ltd, UK). Insulin sensitivity was assessed by the revised quantitative insulin 173 
sensitivity check index (RQUICKI: 1/(log glucose (mg/dL) + logInsulin (µU/mL) + logFFA 174 
(mmol/L))). Serum adiponectin analysis was measured using Quantikine ELISA kits (R&D 175 
Systems, UK). Inter-assay CV was 6.8% and intra-assay CV was 2.5%. 176 
Erythrocyte and NEFA fatty acid composition 177 
Blood was collected into EDTA vacutainers, erythrocyte lipids and NEFA were extracted as 178 
previously described [21].  NEFA were isolated on thin layer chromatography (Partisil®, Whatman 179 
international Ltd, Kent, UK) and transesterified with toluene:methanol:acetyl chloride, 20:80:10 180 
(v/v) [24]. The FA methyl esters obtained from erythrocytes and NEFA fractions were separated on 181 
an Agilent 6890 Gas Chromatograph (Agilent Technologies UK Ltd, UK) fitted with a flame 182 
ionization detector with a 25 m BP75 capillary column [21]. The injection volume was 2 µL, the 183 
temperature was 160ºC for 4 min and then rose to 200ºC in 10 min (gradient of 12ºC/min). 184 
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Statistical analysis 185 
Data were tested for normality and analysed per protocol using SPSS version 17.0. Data were 186 
analysed by analysis of covariance (ANCOVA) of endpoint values, adjusted for ethnicity, age, BMI 187 
and baseline value. Normality of the residuals was checked for analysis and log transformation of 188 
the data was attempted when required.  189 
 190 
RESULTS 191 
Of the 57 individuals assessed for eligibility, 49 were randomized to one of the three treatment 192 
groups (Figure 1). One participant in the EPA-supplemented group dropped out of the study (lost to 193 
follow-up). No adverse effects were reported. The baseline characteristics of the 48 participants that 194 
completed the study (16 per group) are described in Table 1. Body weight and body composition 195 
remained unchanged throughout the 6 wks intervention. 196 
Compliance to treatment 197 
The omega-3 index (proportion of EPA+DHA in erythrocyte) increased by 2.7% weight of total 198 
fatty acids (95% CI, +1.5, +4.0, P = 0.009) in the DHA-supplemented group and 3.9% (95%CI, 199 
+2.7, +5.1, P < 0.001) in the EPA-supplemented group. The proportion of EPA in erythrocyte 200 
membrane following EPA-rich treatment was greater by 3.0% (95% CI [2.3, 3.8], P < 0.001) and 201 
DPA n-3 (22:5n-3) by 1.0% (95% CI [0.6, 1.4], P < 0.001) compared to olive oil. Erythrocyte DHA 202 
was higher by 1.8% (95% CI [0.5, 3.1], P = 0.004) and erythrocyte DPA lower by 0.4% (95% CI 203 
[0.0, 0.8], P = 0.039) after DHA-rich treatment compared with olive oil. In NEFA, the proportion of 204 
EPA (P < 0.001), DPA n-3 (P < 0.001) and DHA (P = 0.004) were greater in the EPA-205 
supplemented group, while DHA was higher in the DHA-supplemented group (P = 0.024) 206 
compared with olive oil. The fatty acid composition of all individual erythrocyte lipids and NEFA 207 
are presented in tables 2 and 3, respectively. 208 
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PMA, vascular function and associated markers  209 
Baseline values did not differ between the groups (ANOVA, adjusted for age, BMI and ethnicity). 210 
Supplementation with EPA- and DHA-rich oils had no effect on PMA, functional capillary density, 211 
plasma 8-isoprostanes-F2α, nor the indices of arterial function measured by PWA and DVP (Table 212 
4). Night-time ambulatory HR was reduced by 6.5 bpm (95% CI [-12.2, -0.8], P = 0.021) in the 213 
DHA-supplemented group compared to the EPA-supplemented group, while day-time and 24h 214 
ambulatory BP and HR remained unchanged by treatment (table 5).  215 
Plasma lipids and insulin sensitivity 216 
There was a statistically significant treatment effect on total NEFA concentrations (P = 0.048)   217 
(Table 6), although post hoc pairwise comparisons were not statistically significantly different:  218 
EPA, -0.12 mmol/L (95% CI [-0.25, 0.00], P = 0.061); DHA, -0.10 mmol/L (95% CI [-0.23, 0.03], 219 
P = 0.180) compared to olive oil (Bonferroni post hoc multiple comparison test). RQUICKI was 220 
higher by 0.056 (95% CI [0.010, 0.102], P = 0.012) in the EPA-supplemented group compared to 221 
olive oil (after Bonferroni adjustment). Glucose, insulin and adiponectin concentrations, TC, 222 
triglycerides, LDL, HDL, Apolipoprotein B, triglycerides:HDL, TC/HDL and Apolipoprotein 223 
B/LDL ratios did not differ between the groups (Table 6). 224 
 225 
DISCUSSION 226 
It is crucial to understand how EPA and/or DHA may affect markers of CVD risk in order to 227 
optimise their respective proportions in dietary supplements. The EPA and DHA trial was, to our 228 
knowledge, the first human intervention to look at the separate effect of the two marine FA on 229 
platelet monocyte aggregation, a true indicator of in vivo platelet aggregation and an early marker of 230 
CVD risk. Because literature is scarce on this individual effect, other markers of CVD risk were 231 
included as secondary outcomes in order to further our understanding of the field. Neither EPA nor 232 
DHA had an effect on PMA, vascular function or lipoprotein profiles. 233 
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EPA and DHA increased their respective forms in erythrocyte membranes and the plasma NEFA 234 
fraction, suggesting good compliance to capsule intake. Erythrocyte DPA, but not DHA, was higher 235 
following EPA-rich treatment, confirming elongation beyond DPA is limited. In contrast, both DPA 236 
and DHA were greater following EPA supplementation in NEFA, suggesting that conversion from 237 
EPA to DHA may occur, as documented before [25]. There is evidence that EPA is preferentially 238 
incorporated into phospholipids, cholesterol esters [26] and LDL particles [27], and that DHA 239 
appears to be preferentially directed to tissues [26, 28]. However, the effect of fish oil 240 
supplementation on fasting NEFA patterns has been poorly studied. Fasting NEFA composition 241 
appears to reflect adipose tissue fatty acid profiles, although NEFA and subcutaneous adipose tissue 242 
EPA and DHA have been shown to be poorly related following fish oil supplementation [29]. The 243 
NEFA fraction may be influenced by the composition of other lipid fractions or tissues and further 244 
work in this area may help understand the differential roles of EPA and DHA in cardiovascular 245 
health. 246 
Our results contrast with previous placebo-controlled trials showing that both EPA and DHA alone 247 
could reduce platelet activation and aggregation [30, 31]. However these studies measured ex vivo 248 
platelet activation, while the present method is believed to represent platelet activation in vivo more 249 
accurately [6]. It was previously shown that mackerel consumption (~ 1 g EPA+DHA/d, 4 wks) 250 
reduced PMA in healthy young men [16]. The difference in outcome might be due to individual 251 
variability, as well as the presence of other components in mackerel, such as selenium or vitamins 252 
[32]. Consistent with this, the same authors recently reported that fish oil supplementation (2 g/d, 6 253 
wks) had no effect on PMA and other markers of platelet monocyte activation in CHD patients [17]. 254 
Corroborating the results on platelet function, we found that neither EPA nor DHA altered 255 
measurements of vascular function. Microvascular function has received little attention with regard 256 
to potential effects of n-3 PUFA, but limited previous research suggests DHA, but not EPA, may 257 
improve forearm microcirculation [33]. Functional capillary density is an early structural indicator 258 
of microvascular abnormalities associated with hypertension [34]. It remained unchanged by EPA 259 
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and DHA, perhaps unsurprisingly, in this normotensive subject group. The lack of effect on 260 
functional capillary density may be due to the young age and metabolic good health of the 261 
population group studied. Indices of arterial stiffness and pulse wave reflection, as measured by 262 
DVP and PWA augmentation index, remained unchanged upon EPA and DHA-rich treatment. This 263 
is consistent with a recent study in which a 12-month fish oil intervention failed to improve arterial 264 
stiffness in an older healthy population [21]. This suggests that daily doses of EPA and DHA (~2-265 
3g), provided together or individually, are not able to improve central and peripheral indices of 266 
arterial stiffness/vascular tone, in healthy subjects. 267 
Plasma 8-isoprostane-F2α concentrations remained unchanged following both treatments. 268 
Previously, 8-isoprostane-F2α concentrations increased postprandially following an EPA-rich high-269 
fat meal in healthy men, although levels decreased following a DHA-only meal [35, 36], supporting 270 
suggestions that EPA and DHA initiate the generation of different oxidized fatty acid metabolites. 271 
Chronic intake of EPA and DHA appears to have no effect in healthy men, although it has been 272 
observed that fish oils may reduce oxidative stress and lipid peroxidation in populations at higher 273 
risk of CVD, and possibly at lower doses [37]. 274 
Meta-analyses have convincingly established the TAG lowering effect of fish oils, in both 275 
normolipidaemic and hyperlipidaemic subjects [38, 39]. This effect is dose-dependent and greater in 276 
individuals with higher baseline concentrations [38]. Fasting plasma TAG concentrationss were low 277 
in the present study (mean 0.9 mmol/L), which may explain why there was no TAG lowering effect. 278 
The lack of effect on cholesterol levels confirms that fish oils are unlikely to exert a 279 
cardioprotective effect through a role in cholesterol metabolism [39, 40]. EPA, but not DHA, 280 
improved RQUICKI compared to placebo. This was not supported by changes in adiponectin 281 
concentrations, and confirmation with a gold standard measure of insulin sensitivity is required. 282 
A key factor in the lack of effect of treatment might be that participants were healthy (free of 283 
cardiovascular disease or other significant cardio-metabolic disorder), and some were recruited in 284 
local gymnasiums and therefore may have been particularly health conscious, which would limit the 285 
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scope for improvement in CVD risk factors. It should be noted that the baseline omega-3 index was 286 
6.8 % (+/-1.6%) (supplement material 2), approaching the 8% target suggested by Von Schacky in 287 
2004 to reduce the risk of coronary heart disease [41]. Although our intervention improved this 288 
index to values above this target (10.5% and 9.3% in the EPA- and DHA-treated group, 289 
respectively), it may be advisable to recruit populations with a lower omega-3 index in future trials. 290 
The main advantage in investigating cardiovascular health effects in a healthy young group of males 291 
is that this approach enables investigation of potential preventative effects, and avoids confounding 292 
effects of age or sex. A limitation of the study is that the final sample size of 13-16 per group may 293 
have resulted in insufficient statistical power to detect the small changes that would be expected in 294 
this population. Furthermore, capsules were supplied in different sizes according to treatment, 295 
preventing full double-blinding of treatment allocation. Strengths include the sensitive, validated 296 
technical approach to measurement of oxidative stress and platelet function (isoprostanes, PMA), 297 
and the randomized design. The PMA measurements represent the true ‘in vivo’ platelet function, 298 
unlike most techniques previously used that measure ex vivo aggregation. The effects of fish oil 299 
supplementation on capillary density have rarely been reported. The findings reported here are only 300 
relevant to healthy young males, and it seems likely that fish oils do not bring additional health 301 
benefits to a population at low cardiovascular risk when provided at 3g/d for 6 wks. However, an 302 
additional treatment group receiving combined EPA+DHA was not included in the design, and the 303 
possibility that EPA and DHA exert a complementary effect cannot be excluded. 304 
 305 
CONCLUSION 306 
In conclusion, an in vivo marker of platelet function was not responsive to supplementation 307 
with approximately 3g/d of long-chain n-3 PUFA, either in the form of EPA or DHA, compared 308 
with olive oil in young men at low risk of CVD. Although the oils were either rich in EPA or DHA, 309 
and the study design did not include a combined EPA+DHA treatment, these findings support 310 
current views that fish oil supplements have little effect on CVD risk in healthy populations [21, 311 
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40], especially if they present a high omega-3 index, low TAG values, or other characteristics 312 
indicating a particularly healthy status. While this relatively small study reports mechanistic 313 
outcomes rather than validated markers of predicted CVD risk, these findings draw further attention 314 
to the importance of defining inclusion criteria and cut off values for healthy populations in fish oil 315 
supplementation trials, which may greatly affect the outcome of such interventions.  316 
 317 
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TABLES 
Table 1: Baseline characteristics of the participants 
 
Placebo 
(n=16) 
EPA  
(n=16) 
DHA 
(n=16) 
P value 
Age (y) 25.8 (7.4) 25.8 (7.5) 27.9 (8.0) 0.6632 
BMI (kg/m2) 23.6 (3.4) 22.9 (3.0) 23.3 (2.9) 0.8052 
Waist circumference (cm) 81.7 (10.2) 78.4 (7.4) 82.5 (10.3) 0.4592 
Systolic BP (mmHg) 119.5 (10.4) 119.5 (13.5) 124.2 (10.7) 0.4282 
Diastolic BP (mmHg) 66.7 (6.3) 67.9 (11.8) 70.9 (8.7) 0.4202 
Fasting plasma glucose (mmol/L) 4.9 (0.3) 5.1 (0.3) 5.3 (0.4) a 0.0102 
Fasting triglycerides1 (mmol/L) 0.8 (0.3) 0.9 (0.4) 0.8 (0.3) 0.4202 
TC:HDL-C ratio 3.2 (0.7) 3.4 (0.8) 3.5 (0.8) 0.5462 
Ethnicity    White/Caucasian 
                   Black 
                   Indian/Middle East 
                   Asian                    
9 
2 
4 
1 
12 
1 
2 
1 
9 
2 
3 
2 
0.9043 
 
Mean values ± SD.; TC: total cholesterol, HDL-C: high density lipoprotein cholesterol 
1
 geometric means.  
2
 P values are from univariate analysis of the variances of the screening values by treatment 
3 P value is from Pearson’s Chi-square test of ethnicity by treatment. 
a
 P < 0.05 compared to placebo and DHA-supplemented groups, Bonferroni’s multiple comparison 
test  
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Table 2: Erythrocyte fatty acid composition (%) at baseline and after 6 wks of supplementation in healthy men with olive oil (placebo), 
EPA- or DHA-rich oils (3g/d). 
  Baseline (n=46) Placebo (n=15) EPA (n=16) DHA (n=15) P value 
16:0 (PA) 17.0  (2.8) 17.5  (3.1) 18.4  (1.7) 17.0  (3.1) 0.226 
16:1n-7  0.3  (0.1) 0.5  (0.5) 0.3  (0.1) 0.3  (0.1) 0.91 
18:0 (SA) 15.3  (1.5) 15.3  (1.1) 15.7  (1.3) 15.3  (1.9) 0.44 
18:1 trans  0.2  (0.1) 0.2  (0.1) 0.2  (0.1) 0.2  (0.1) 0.675 
18:1n-9  14.9  (1.2) 14.8  (1.1) 14.6  (1.3) 15.3  (1.4) 0.142 
18:1n-7  1.2  (0.2) 1.3  (0.1) 1.2  (0.1) 1.2  (0.2) 0.128 
18:2n-6 (LA) 12.1  (1.1) 12.2  (1.6)a 10.4  (1.7)b 11.3  (1.3)a,b 0.003 
18:3n-3 (ALA) 0.2  (0.1) 0.2  (0.04) 0.17  (0.1) 0.2  (0.04) 0.144 
20:3n-6 (DGLA) 2.2  (0.6) 2.3  (1.0)a 1.7  (0.4)b 2.0  (0.7)a,b 0.01 
20:4n-6 (AA) 17.3  (2.2) 17.1  (2.2)a 15.1  (1.9)b 16.9  (2.9)a < 0.001 
20:5n-3 (EPA) 1.1  (0.4) 1.1  (0.4)a 4.2  (1.4)b 1.6  (0.6)a < 0.001 
22:4n-6  3.6  (0.9) 3.6  (0.8)a 2.7  (0.9)b 3.4  (1.1)a 0.003 
22:5n-6  0.6  (0.1) 0.6  (0.1)a 0.4  (0.1)b 0.6  (0.1)a < 0.001 
22:5n-3 (DPA) 3.3  (0.6) 3.3  (0.6)a 4.3  (0.4)b 3.1  (0.6)a < 0.001 
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22:6n-3 (DHA) 5.7  (1.53) 6.0  (1.3)a 6.3  (1.2)a,b 7.7  (2.0)b 0.025 
Omega-3 index (EPA+DHA) 6.8 (1.6) 7.1 (1.4)a 10.5 (2.4)b 9.3 (2.4)b  < 0.001 
 
Values are geometric means (SD) , expressed in percentage weight of total fatty acids. PA: palmitic acid, SA: stearic acid, LA: linoleic 
acid, ALA: alpha-linolenic acid, DGLA: dihomo-gamma-linolenic acid, AA: arachidonic acid, EPA: Eicosapentaenoic acid, DPA: 
docosapentaenoic acid, DHA: docosahexaenoic acid.  
P value is from univariate analysis of variance of the follow-up value by treatment with baseline value, ethnicity, BMI and age as 
covariates. Values in the same row with different superscripts are significantly different from each other P<0.05 using Bonferroni’s test for 
3 comparisons. 
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Table 3: NEFA composition (%) at baseline and after 6 wks of supplementation in healthy men with olive oil (placebo), EPA- or DHA-
rich oils (3g/d). 
 
Baseline (n=46) Placebo (n=16) EPA (n=16) DHA (n=16) P value 
16:0 (PA) 41.7 (6.5) 37.6 (6.8) 38.5 (8.0) 39.9 (7.3) 0.630 
16:1n-7 2.3 (1.0) 2.2 (0.8) 2.6 (1.0) 2.2 (0.9) 0.889 
18:0 (SA) 15.2 (5.0) 16.7 (3.5) 15.8 (5.0) 16.6 (4.6) 0.898 
18:1n-9 15.4 (9.4) 20.2 (8.0)a 14.3 (7.7)b 15.9 (8.4)a,b 0.035 
18:2n-6 (LA) 4.9 (4.0) 7.2 (3.4) 5.6 (4.2) 4.6 (5.2) 0.655 
18:3n-3 (ALA) 1.7 (0.7) 1.5 (0.6) 1.8 (0.7) 1.6 (0.6) 0.066 
18:3n-6 (GLA) 0.0 (0.2) 0.0 (0.2) 0.0 (0.2) 0.0 (0.2) 0.409 
20:3n-6 (DGLA) 0.6 (0.4) 0.6 (0.2) 0.5 (0.4) 0.8 (0.3) 0.280 
20:4n-6 (AA) 1.5 (0.9) 1.4 (0.4) 1.8 (1.2) 1.9 (1.0) 0.077 
20:5n-3 (EPA) 0.0 (0.2) 0.4 (0.9)a 1.8 (2.9)b 0.5 (0.5)a <0.001 
22:4n-6 2.8 (2.1) 3.1 (3.0) 3.1 (3.0) 3.1 (3.7) 0.328 
22:5n-6 0.0 (0.3) 0.3 (0.1) 0.3 (0.4) 0.3 (0.2) 0.086 
22:5n-3 (DPA) 0.0 (0.2) 0.0 (0.3)a 0.6 (0.7)b 0.0 (0.3)a 0.004 
22:6n-3 (DHA) 0.8 (0.3) 0.8 (0.7)a 1.7 (1.8)b 1.5 (1.6)b <0.001 
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Values are geometric means (SD), expressed in mass percentage of total NEFA composition. PA: palmitic acid, SA: stearic acid, LA: 
linoleic acid, ALA: alpha-linolenic acid, GLA: gamma-linolenic acid, DGLA: dihomo-gamma-linolenic acid, AA: arachidonic acid, EPA: 
Eicosapentaenoic acid, DPA: docosapentaenoic acid, DHA: docosahexaenoic acid.  
P value is from univariate analysis of variance of the endpoint values by treatment with baseline values, ethnicity, BMI and age as 
covariates. Values in the same row with different superscripts are significantly different from each other, P<0.05 using Bonferroni’s test for 
3 comparisons.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
23 
 
 
Table 4: Platelet mononuclear cell aggregates, capillary density, plasma 8-isoprostanes-F2α, and parameters of vascular function at 
baseline and changes after 6 wks of supplementation in healthy men with olive oil (placebo), EPA- or DHA-rich oils (3g/d). 
  
Olive Oil (n = 15) EPA (n = 15) DHA (n = 15) P value4 
PMA (CD14+/CD42b+) (% total CD14+) Baseline 9.6 ± 1.8 7.9 ± 2.6 8.2  ± 2.2 
 
Change -0.5 (-2.0, 1.04)1 0.4 (-0.8, 1.6)2 0.3 (-1.5, 2.0)1  0.917 
Capillary density count (capillaries/mm2) Baseline 65.0 ± 8.6 68.9 ± 12.0 69.4 ± 6.5 
 
Change 4.0 (-1.7,  9.7) 2.0 (-1.8, 5.8) 0.4 (-6.3 , 7.0)3 0.773 
Plasma 8-isoprostanes (ng/L) Baseline 75.2 ± 36.1 88.1 ± 28.3 76.5 ± 30.4 
Change 3.3 (-5.6, 12.3) 1.0 (-13.7, 15.7) -7.2 (-24.0 , 9.6)1 0.261 
Stiffness index, m/s 
Baseline 5.7 (0.4) 6.12 (0.8) 6.1 (1.6) 
0.706 
Change -0.0 (-0.5 , 0.4 )1 -0.2 (-0.6 , 0.1 ) -0.0 (-0.2 , 0.1 ) 
Reflection index, % 
Baseline 65.4 (11.9) 68.0 (11.3) 64.6 (11.7) 
0.797 
Change 0.8 (-8.8 , 10.3 )1 -1.6 (-6.5 , 3.4 ) 0.2 (-6.7 , 7.0 ) 
Peripheral AIx, % 
Baseline 54.0 (9.0) 53.7 (13.2) 50.0 (15.1) 
0.645 
Change -2. 5 (-6.6 , 1.7 )1 -3.5 (-8.5 , 1.5 ) 0.3 (-3. 7 , 4.3 ) 
Central AIx, % 
Baseline 112.2 (8.3) 110. 6 (11.3) 108.4 (11.0) 
0.560 
Change -2.1 (-6.9 , 2.7 )1 -2.9 (-8.7 , 2.8 ) -2.6 (-6.1 , 0.9 ) 
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Mean ± SD or mean change (95% CI); PMA: platelet monocyte aggregates, SBP: systolic blood pressure, DBP, diastolic blood pressure, 
HR: heart rate, AIx: Augmentation index 
PMA are expressed as percentage of total gated monocytes; AIx = P2/P1, where P1 and P2 are the pressure of the forward (systolic) and 
reflected (diastolic) wave, respectively. 
1 
n=13, 2 n=14 , 3 n=12, 
4
 P values are from univariate analysis of variances of the endpoint values by treatment with baseline values, ethnicity, BMI and age as 
covariates.  
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Table 5: Ambulatory blood pressure and heart rate at baseline and after 6 wks of supplementation in healthy men with olive oil (placebo), 
EPA- or DHA-rich oils (3g/d). 
 
  Olive Oil (n = 15) EPA (n = 14) DHA (n = 15) P value 
Day      
SBP (mmHg) 
Baseline 122.8 (10.5) 124.9 (8.6) 125.2 (7.7)  
Change -0.5 (-4.2 ; 3.3) -1.9 (-6.1 ; 2.2) -1.9 (-6.1 ; 2.2) 0.859 
DBP (mmHg) 
Baseline 72.0 (6.8) 75.1 (5.3) 72.3 (7.8)  
Change 0.3 (-2.9 ; 3.5) -1.8 (-4.2 ; 0.6) -1.0 (-3.7 ; 1.7) 0.643 
HR (bpm) 
Baseline 65.9 (7.7) 70.2 (10.9) 67.1 (9.0)  
Change 1.8 (-2.1 ; 5.8) 0.1 (-5.9 ; 6.2) -0.5 (-3.8 ; 2.7) 0.580 
Night      
SBP (mmHg) 
Baseline 101.1 (8.3) 107.2 (10.8) 103.7 (8.0)  
Change 0.9 (-3.8 ; 5.6) 0.7 (-4.5 ; 5.9) 1.4 (-3.7 ; 6.5) 0.246 
DBP (mmHg) 
Baseline 55.4 (4.7) 61.1 (3.8) 58.7 (6.4) 
 
Change 3.3 (-0.5 ; 7.0) 1.8 (-0.9 ; 4.5) 0.5 (-3.1 ; 4.1) 0.392 
HR (bpm) 
Baseline 54.8 (5.4) 56.9 (7.0) 56.5 (8.0)  
Change -0.2 (-5.3 ; 4.9)a,b 3.0 (-1.2 ; 7.2)a -2.7 (-5.4 ; 0.1)b 0.021 
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24h      
SBP (mmHg) 
Baseline 117.4 ± 9.5 121.0 ± 8.5 120.5 ± 7.1  
Change -1.4 (-5.3, 2.6) -1.6 (-5.3, 2.0)2 -2.1 (-5.6, 1.5) 0.663 
DBP (mmHg) 
Baseline 70.3 ± 10.7 72.1 ± 4.8 69.3± 6.9  
Change -2.4 (-8.6, 3.9) -1.1 (-3.4 , 1.1)2 -1.3 (-3.2, 0.7) 0.061 
HR (bpm) 
Baseline 62.5 (6.7) 67.4 (9.9) 64.5 (8.5)  
Change 0.9 (-3.2 ; 5.0) 0.5 (-4.9, 5.9)2 -1.3 (-3.9 ; 1.2) 0.186 
 
Data are presented as means (SD) and changes from baseline are expressed as mean of the differences (CI 95%).   
P values are from univariate analysis of variance of the endpoint values by treatment with baseline values, ethnicity, BMI and age as 
covariates. 
Values in the same row with different superscripts are significantly different from each other, P<0.05 using Bonferroni’s test for 3 
comparisons. 
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Table 6: Plasma lipid concentrations and indices of glycaemic control and insulin sensitivity at baseline and after 6 wks of 
supplementation in healthy men with Olive Oil (placebo), EPA or DHA (3g/d).  
  Olive Oil (n=16) EPA (n=16) DHA (n=16) P value2 
Total cholesterol 
(mmol/L) 
Baseline 4.75 ± 0.72 4.69 ± 0.97 4.45 ± 0.67  
Change -0.10 (-0.46, 0.26) 0.00 (-0.38, 0.38) 0.18 (-0.15, 0.51) 0.673 
Triglycerides (mmol/L) Baseline 0.88 ± 0.31 0.97 ± 0.45 0.87 ± 0.43  
Change -0.11 (-0.26, 0.03) -0.26 (-0.46, -0.07) -0.12 (-0.30, 0.07) 0.396 
HDL-C1 (mmol/L) Baseline 1.49 ± 0.36 1.45 ± 0.28 1.37 ± 0.29  
Change 0.02 (-0.17, 0.21) 0.16 (-0.04, 0.35) 0.06 (-0.03, 0.15) 0.680 
LDL-C (mmol/L) Baseline 2.87 ± 0.57 2.81 ± 0.76 2.68 ± 0.54  
Change -0.07 (-0.34, 0.20) -0.04 (-0.28, 0.19) 0.18 (-0.05, 0.41) 0.404 
NEFA (mmol/L) Baseline 0.32 ± 0.09 0.38 ± 0.16 0.37 ± 0.24  
Change 0.05 (-0.04, 0.14) -0.09 (-0.20, 0.01) -0.08 (-0.19, 0.03) 0.048 
TC:HDL-C ratio Baseline 3.34 ± 0.80 3.31 ± 0.64 3.38 ± 0.80 
Change -0.13 (-0.38, 0.13) -0.24 (-0.42, -0.06) -0.06 (-0.25, 0.13) 0.367 
Apolipoprotein B (g/L) Baseline 0.88 ± 0.19 0.90  ± 0.23 0.80 ± 0.25  
Change -0.07 (-0.19, 0.05) -0.06 (-0.11, -0.01) 0.08 (-0.05, 0.21) 0.264 
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Glucose (mmol/L) Baseline 5.0 ± 0.3 5.2 ± 0.4 5.3 ± 0.3  
Change 0.1 (-0.2, 0.4) -0.0 (-0.4, 0.3) -0.0 (-0.2, 0.2) 0.935 
Insulin1 (mU/L) Baseline 5.4 (3.1) 5.6 ± 2.2 6.4 ± 5.1  
Change 1.4 (-0.3, 3.1) 0.8 (-1.3, 3.0) 0.3 (-1.3, 1.9) 0.826 
Adiponectin (µg/L) Baseline 6.7 ± 2.8 7.2 ± 3.6 7.5 ± 3.5  
Change 1.4 (0.1, 2.8) 0.7 (-0.9, 2.2) 0.0 (-1.0, 1.0) 0.281 
RQUICKI Baseline 0.47 ± 0.06 0.45 ± 0.04 0.45 ± 0.08  
Change -0.03 (-0.07, 0.01) 0.04 (-0.01, 0.08)a 0.00 (-0.03, 0.03)  0.014 
Mean ± SD or mean change (95% CI); HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol (LDL-C); 
NEFA, non-esterified fatty acids; TC, total cholesterol; RQUICKI, revised quantitative insulin sensitivity check index. 
1
 geometric mean with loge ratio of change from baseline 
2 P values are from univariate analysis of variances of the endpoint values by treatment with baseline values, ethnicity, BMI and age as 
covariates.  
a
 significantly different from olive oil and DHA P<0.05, Bonferroni comparison test 
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FIGURE LEGENDS 
Figure 1: CONSORT flow chart of participants in the EPA and DHA trial  
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• We investigated the separate effects of EPA and DHA supplementation (3g/d, 6wks) 
on vascular and platelet function in healthy young males 
• Neither EPA nor DHA influenced platelet monocyte aggregates or capillary density 
• EPA, but not DHA, improved a marker of insulin sensitivity 
 
